Published on 29/11/2025

Decontamination: VHP/HPV in ATMP Facilities

Advanced Therapy Medicinal Products (ATMPs) are at the forefront of biopharmaceutical innovation, requiring stringent bioburden and viral safety controls to ensure patient safety. One critical component of maintaining sterility in ATMP facilities is decontamination, particularly through the use of Vaporized Hydrogen Peroxide (VHP) and Hydrogen Peroxide Vapor (HPV) methods. This tutorial will guide you through the essential considerations and methodologies for effectively implementing VHP/HPV systems in ATMP manufacturing environments, focusing on compliance with relevant regulatory frameworks, including FDA process validation and EU guidelines.

Understanding VHP/HPV Systems

Vaporized Hydrogen Peroxide is a potent antimicrobial agent commonly used in pharmaceutical manufacturing for its efficacy against a broad spectrum of microorganisms, including viruses, bacteria, fungi, and spores. The process involves the generation of vaporized hydrogen peroxide (VHP) in a closed environment, which penetrates surfaces and equipment to achieve sterilization.

In ATMP facilities, which often utilize closed systems and single-use systems, adopting VHP/HPV provides a reliable method for ensuring sterility between production runs while adhering to regulatory compliance measures such as Aseptic Controls Annex 1. This section discusses the principles of VHP/HPV systems in biological manufacturing, the advantages of using such methods, and the implementation challenges.

The Mechanism of Action

The effectiveness of VHP hinges on its ability to release reactive hydroxyl radicals and other oxidizing agents that disrupt cellular functions and kill microbial organisms. The critical parameters that govern the effectiveness of VHP disinfection include:

• Concentration of hydrogen peroxide – Typically, 30% to 35% solution is used.
• Exposure time – Ranges from 30 minutes to several hours, depending on the load and environmental conditions.
• Temperature and humidity – Optimal parameters often target temperatures between 20°C to 30°C and relative humidity levels of approximately 45% to 75%.

Regulatory Framework and Guidelines

As part of your validation strategy, it is vital to reference pertinent regulatory guidelines to align your VHP/HPV decontamination strategy. Key documents include:

• FDA Process Validation Guidance
• ICH Q5A(R2) regarding viral safety evaluation
• EMA and MHRA guidelines relevant to ATMPs, particularly around viral clearance validation

Incorporating these guidelines ensures that your decontamination processes are compliant and lead to successful validation outcomes.

Designing a VHP/HPV Validation Plan

Establishing a robust validation plan for VHP/HPV systems is critical for ensuring regulatory compliance and effectiveness. The following steps will help you structure your validation efforts appropriately.

Step 1: Define the Validation Objectives

The primary objectives should include:

• Demonstration of efficacy against pathogens and spores as specified in the aseptic controls Annex 1.
• Assessment of potential impacts on product quality attributes, such as potency identity CQAs.
• Documentation of the integrity of closed systems and single-use systems post-decontamination.

Step 2: Risk Assessment

Conduct a comprehensive risk assessment to identify potential microbial contamination sources and assess the inherent risks associated with the production process. Factors to consider include:

• Chain of identity custody (COI) – Ensuring that materials and equipment used throughout the process maintain sterility.
• Chain of custody (COC) – Tracking and maintaining control throughout the manufacturing stages.

A refinement of risk parameters informs the development of tailored virus clearance validation protocols.

Step 3: Develop Qualification Protocols

Create specific qualification protocols focusing on:

• Installation Qualification (IQ) – Verifying that the VHP system is installed according to manufacturer specifications.
• Operational Qualification (OQ) – Ensuring that the system operates as intended under normal operating conditions.
• Performance Qualification (PQ) – Demonstrating the effectiveness of the VHP system against specified bioburden.

Executing Spiking Studies for Viral Clearance Validation

A critical component of validating VHP/HPV systems in ATMP facilities involves conducting spiking studies. These studies provide essential data to assess the efficacy of decontamination and its effect on viral clearance.

Step 1: Study Design

Begin with the design of a well-structured spiking study that includes:

• Selection of representative viral strains – Choose strains relevant to the production process.
• Establishment of spiking concentrations – Use levels that challenge the VHP/HPV system effectively.
• Selection of filtration and test methods to measure viral clearance.

Step 2: Implementation

During execution, follow comprehensive procedures to ensure that:

• Viral loads are accurately measured before and after VHP decontamination.
• Sample collection is consistent with regulatory requirements (e.g., FDA process validation guidance).

Step 3: Data Analysis

The data collected during spiking studies must be analyzed to determine:

• The log reduction of viral loads following decontamination.
• Consistency of results across multiple studies and areas within the facility.

This analytical approach helps reinforce the reliability and effectiveness of the VHP/HPV methods used in the ATMP manufacturing process.

Tailoring PPQ and CPV for ATMP Production

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) are essential practices for ensuring the long-term effectiveness of decontamination strategies in ATMP manufacturing. Tailoring these for specific systems requires targeted considerations.

Step 1: Establish PPQ Parameters

During PPQ, focus on:

• Documenting all critical process parameters relevant to VHP/HPV.
• Defining acceptance criteria for bioburden and effectiveness post-decontamination.
• Incorporating real-world scenarios that closely mimic manufacturing conditions.

Step 2: Develop a CPV Plan

The CPV plan should outline how to continuously monitor and verify VHP/HPV efficacy, incorporating:

• Routine checks of equipment integrity and performance.
• Regular updates to training and procedural documents to reflect best practices and quality assurance measures.

Step 3: Continuous Monitoring and Adjustment

Adopt a proactive approach towards monitoring operational conditions, which may involve periodic assessments and adjustments based on observed outcomes and evolving regulatory expectations.

Conclusion

Implementing effective VHP/HPV decontamination protocols in ATMP facilities requires a structured approach aligned with regulatory standards. Following the outlined steps will facilitate the establishment of a reliable, compliant, and scientifically grounded framework for maintaining aseptic conditions in biologics manufacturing. Ongoing vigilance and adherence to best practices during validation will ensure that ATMPs are produced safely and effectively, securing trust and regulatory approval in the dynamic field of advanced therapeutics.